Chetachi A. Emeremni

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

Lucio Crinò, Myung‐Ju Ahn, Filippo de Marinis et al. · Journal of Clinical Oncology · 2016 · 351 citations · Full text

Medicine, Oncology, Pharmacology +17

Racial/ethnic disparities in contraceptive use: variation by age and women's reproductive experiences

Christine Dehlendorf, Seo‐Young Park, Chetachi A. Emeremni et al. · American Journal of Obstetrics and Gynecology · 2014 · 174 citations · Full text

Medicine, Demography, Obstetrics +16

Prospective Evaluation of a Clinical Pathway for Suspected Appendicitis

Ashley Saucier, Eunice Y. Huang, Chetachi A. Emeremni et al. · PEDIATRICS · 2013 · 117 citations · Full text

Medicine, Emergency Medicine, Pediatrics +17

ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).

Enriqueta Felip, Sergey Orlov, Keunchil Park et al. · Journal of Clinical Oncology · 2015 · 78 citations

Medicine, Oncology, Pharmacology +13

ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).

Tony Mok, David R. Spigel, Enriqueta Felip et al. · Journal of Clinical Oncology · 2015 · 77 citations

Medicine, Oncology, Pharmacology +16